Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial
Roshan Siva,1 Mona Bafadhel,2 William Monteiro,3 Christopher E Brightling,3 Ian D Pavord2
1Department of Respiratory Medicine, Croydon University Hospital, Croydon Health Services NHS Trust, London, 2Department of Respiratory Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus, Oxford, 3Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK
Rationale: Airway inflammation persists after smoking cessation in established chronic obstructive pulmonary disease (COPD), suggesting that other factors drive the airway inflammatory response.
Objectives: We tested the hypothesis that high levels of bacterial colonization are associated with increased levels of neutrophilic airway inflammation in stable COPD by examining the cross-sectional relationship between these measurements and by conducting a randomized, double-blind, placebo-controlled study of the effect of levofloxacin in patients with stable COPD.
Methods: Patients were randomized to receive either levofloxacin 500 mg daily or placebo for 7 days and underwent sputum induction for a differential cell count and quantitative bacterial analysis at baseline and at days 7, 14, and 28.
Results: Sputum percentage neutrophil count correlated with airway bacterial load at baseline (r=0.56; P=0.003). Levofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4–25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 106 cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%–51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7. Change in percentage neutrophil count correlated significantly with baseline airway bacterial load and change in airway bacterial load.
Conclusion: In stable COPD, levofloxacin treatment causes a short-term reduction in bacterial load. This is associated with a reduction in neutrophilic airway inflammation in patients with high bacterial loads. Further studies are required to investigate whether this effect is clinically advantageous.
Keywords: bacteria, antibiotics, sputum
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Webster TJ, Lee S, An SSA
Published Date: 25 August 2015
Novotna B, Koblizek V, Zatloukal J, Plutinsky M, Hejduk K, Zbozinkova Z, Jarkovsky J, Sobotik O, Dvorak T, Safranek P
Published Date: 10 November 2014
The effects of high intensity exercise during pulmonary rehabilitation on ventilatory parameters in people with moderate to severe stable COPD: a systematic review
Osterling K, MacFadyen K, Gilbert R, Dechman G
Published Date: 1 October 2014
Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study
Wurst KE, St Laurent S, Mullerova H, Davis KJ
Published Date: 25 September 2014
Lindgren S, Storli SL, Wiklund-Gustin L
Published Date: 6 May 2014
Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences
Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y
Published Date: 21 January 2014
Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T
Published Date: 20 January 2014
Punekar YS, Shukla A, Müllerova H
Published Date: 9 January 2014
Effect of repeated Waon therapy on exercise tolerance and pulmonary function in patients with chronic obstructive pulmonary disease: a pilot controlled clinical trial
Kikuchi H, Shiozawa N, Takata S, Ashida K, Mitsunobu F
Published Date: 12 December 2013
Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease
Published Date: 30 April 2013